Oncotelic Therapeutics Announces Three Abstracts on Deciparticle Everolimus Accepted for 2025 San Antonio Breast Cancer Symposium

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has announced that three abstracts featuring its investigational intravenous Deciparticle everolimus (Sapu003) have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, scheduled for December 9–12 in San Antonio, Texas. The acceptance of multiple abstracts at this prestigious oncology conference underscores the scientific community's interest in this novel therapeutic approach for hormone receptor-positive, HER2-negative metastatic breast cancer.

Developed by Sapu Nano, a joint venture between Oncotelic and Dragon Oversea, Sapu003 represents a significant advancement in mTOR inhibitor therapy. The intravenous formulation is specifically designed to overcome limitations associated with oral mTOR inhibitors like Afinitor, including poor bioavailability and restricted tumor penetration. By addressing these pharmacological challenges, Deciparticle everolimus could potentially improve treatment outcomes for patients with metastatic breast cancer who have limited therapeutic options.

The three accepted abstracts collectively detail the clinical rationale, molecular biomarkers, and pharmacokinetic data supporting the ongoing Phase 1 trial in HR⁺/HER2⁻ metastatic breast cancer. This comprehensive presentation package provides validation for the scientific approach behind Sapu003 and demonstrates the compound's progression through clinical development. The data presentation at such a prominent symposium indicates peer-reviewed acceptance of the research methodology and preliminary findings.

For patients with metastatic breast cancer, the development of Sapu003 could represent a meaningful advancement in treatment options. Current oral mTOR inhibitors face challenges with variable absorption and limited ability to penetrate tumor tissues effectively. The intravenous Deciparticle formulation aims to provide more consistent drug delivery and enhanced tumor targeting, potentially leading to improved efficacy and reduced side effects. This approach aligns with the growing emphasis on precision medicine in oncology, where drug delivery systems are optimized to maximize therapeutic benefit while minimizing systemic toxicity.

The broader oncology field stands to benefit from the technological innovations demonstrated by Sapu003. Successful development of this nanomedicine approach could establish new standards for mTOR inhibitor delivery and potentially be applied to other cancer types beyond breast cancer. The joint venture structure between Oncotelic and Dragon Oversea exemplifies the collaborative nature of modern drug development, where specialized expertise in nanotechnology combines with clinical development experience to advance novel therapies.

Investors and industry observers can access additional information about Oncotelic Therapeutics through the company's newsroom at https://ibn.fm/OTLC. The upcoming presentations at the San Antonio Breast Cancer Symposium will provide crucial data that could influence both the clinical development pathway and the commercial potential of Deciparticle everolimus. As the Phase 1 trial continues to generate data, the medical community will be watching closely for evidence of improved pharmacokinetic profiles and early efficacy signals that could support further investment in this innovative approach to cancer treatment.